Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2010 1
2011 2
2012 5
2013 12
2014 8
2015 15
2016 11
2017 6
2018 7
2019 11
2020 6
2021 9
2022 9
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.
Best Practice in Interventional Management of Urolithiasis: An Update from the European Association of Urology Guidelines Panel for Urolithiasis 2022.
Geraghty RM, Davis NF, Tzelves L, Lombardo R, Yuan C, Thomas K, Petrik A, Neisius A, Türk C, Gambaro G, Skolarikos A, Somani BK. Geraghty RM, et al. Among authors: neisius a. Eur Urol Focus. 2023 Jan;9(1):199-208. doi: 10.1016/j.euf.2022.06.014. Epub 2022 Aug 1. Eur Urol Focus. 2023. PMID: 35927160 Review.
[Urolithiasis].
Knoll T, Schönthaler M, Neisius A. Knoll T, et al. Among authors: neisius a. Urologe A. 2019 Nov;58(11):1271. doi: 10.1007/s00120-019-01047-1. Urologe A. 2019. PMID: 31690976 German. No abstract available.
[Robotic-assisted radical prostatectomy].
Thomas C, Neisius A, Roos FC, Hampel C, Thüroff JW. Thomas C, et al. Among authors: neisius a. Urologe A. 2015 Feb;54(2):178-82. doi: 10.1007/s00120-014-3665-3. Urologe A. 2015. PMID: 25616764 Review. German.
Future perspectives of flexible ureteroscopy.
Secker A, Rassweiler J, Neisius A. Secker A, et al. Among authors: neisius a. Curr Opin Urol. 2019 Mar;29(2):113-117. doi: 10.1097/MOU.0000000000000575. Curr Opin Urol. 2019. PMID: 30668555 Review.
Outcomes of Flexible Ureteroscopy vs Extracorporeal Shock Wave Lithotripsy for Renal Stones in Pediatric Patients: A European Association of Urology Urolithiasis Guidelines Systematic Review and Meta-Analysis.
Geraghty R, Lombardo R, Yuan C, Davis N, Tzelves L, Petrik A, Jung H, Gambaro G, Tailly T, Neisius A, Skolarikos A, Somani B. Geraghty R, et al. Among authors: neisius a. J Urol. 2023 Dec;210(6):876-887. doi: 10.1097/JU.0000000000003696. Epub 2023 Sep 5. J Urol. 2023. PMID: 37669621
Comparison of Treatment Outcomes for Fluoroscopic and Fluoroscopy-free Endourological Procedures: A Systematic Review on Behalf of the European Association of Urology Urolithiasis Guidelines Panel.
Davis NF, Tzelves L, Geraghty R, Lombardo R, Yuan C, Petrik A, Neisius A, Gambaro G, Jung H, Shepherd R, Tailly T, Somani B, Skolarikos A. Davis NF, et al. Among authors: neisius a. Eur Urol Focus. 2023 Nov;9(6):938-953. doi: 10.1016/j.euf.2023.05.008. Epub 2023 Jun 3. Eur Urol Focus. 2023. PMID: 37277273 Review.
97 results